Neurona Therapeutics’ Post

ArsenalBio’s second program, AB2100, will be studied in a phase 1 clinical trial (NCT06245915) as a potential therapy for clear cell, renal cell carcinoma, a form of #Kidneycancer. Alba Gonzalez-Junca, PhD, Associate Director In-Vivo Translational Pharmacology, will discuss the product's characteristics, including its unique logic gating technology during her poster presentation at #AACR2024. #celltherapy #AB2100

Versatility is one of the things that we love most about VHHs here at Isogenica.  In this clip, our Director of Discovery Marion Cubitt outlines just a few of the ways VHHs can be used as modules to build more sophisticated therapeutics such as bi-specific T cell engagers or cell therapies like Carvykti. To learn more about using VHHs to target therapies like CAR-T, check out our information page here: https://lnkd.in/eqKWPsFr    #vhh #InsideIsogenica #AntibodyEngineering  

Calling all #lupus specialists & researchers: The March edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the efficacy of #CAR-T cell therapy, the role of #belimumab in treating childhood-onset #SLE, and the latest in #SLE diagnosis: https://lnkd.in/euBZmUb7

Artiva Biotherapeutics Upsizes IPO to $167M, Lists on Nasdaq Today Artiva Biotherapeutics has increased its IPO to $167 million and is set to list on Nasdaq under the symbol "ARTV" today. The funds will support the clinical development of AlloNK, a cryopreserved NK cell therapy currently in phase 1 trials for lupus nephritis. This exciting development in NK cell therapy holds promise for advancing treatment options for autoimmune diseases. At Biocytogen, we offer advanced humanized mouse models for autoimmune diseases to support your preclinical research and development needs. Check out our autoimmune related mouse model here: https://lnkd.in/ea4ny3UG #Biotech #IPO #ArtivaBiotherapeutics #NKCellTherapy #AutoimmuneResearch #Biocytogen

Congratulations Adaptimmune on securing the first FDA approval for TCR-T in solid tumors! 🎉 At the forefront of what can be accomplished with cell therapy and changing the treatment landscape for patients with synovial sarcoma! Another Immudex GMP Dextramer customer making major clinical impacts in cell therapy! Check out Adaptimmune's paper from last year characterizing afami-cel using Dextramer reagents (Hong et. al., Nature Medicine 2023).

Congratulations to Dan Kemp, Ph.D., SHIN KANEKO, M.D., Ph.D., Tobias Deuse, MD, and the entire Shinobi Therapeutics team on being awarded grant funding from the Japanese Agency for Medical Research and Development (AMED). This grant will support Shinobi Therapeutics’ lead program working to develop an iPS-T cell therapy targeting GPC3+ solid tumor cancers. "iPS cell therapies have the potential to transform patient care across a wide range of diseases while improving access in populations with high unmet needs, and much of the most exciting work in the field is happening in Japan," said Dan Kemp, Ph.D., CEO at Shinobi. "This AMED grant is a major statement of conviction by the Japanese agency and will help accelerate our lead oncology program toward the clinic." Learn more: https://lnkd.in/eKZgxiVf Robert Weisskoff, Ph.D. │ Chong Xu, Ph.D. │ Kevin Chu │ Brian Yordy, Ph.D. #healthcare #biotech #celltherapy

One of the first drugs that Jeffrey Jonas filed for approval was a Parkinson’s disease treatment. Now, a little over a quarter-century later, after executive roles at Shire and Sage Therapeutics, he’s chairing a young startup with $82 million to test whether an off-the-shelf cell therapy can treat the CNS disorder. Kenai Therapeutics emerged Thursday with the Series A co-led by Alaska Permanent Fund Corporation, The Column Group and Cure Ventures, where Jonas is a partner.... Nick Manusos #celltherapy #ipsc #parkinsonsdisease #cellandgenetherapy #cnsdisease #advancedtherapies #regenerativemedicine #biotech #biotechnology #venturecapital #funding #financing #offtheshelf #82m #lifesciences #healthcare #therapeutics FUJIFILM Diosynth Biotechnologies #seriesa #seriesfinancing

Still time to register for our live webinar presented by Dr. David Corey, Rusty Kelley Professor of Biomedical Research, UT Southwestern University, on "New Mechanisms and Targets for microRNAs Therapeutics". We continue our journey into the world of oligonucleotide therapies with Episode 2: "New Mechanisms and Targets for microRNAs Therapeutics" on September 18th. This episode will delve into the latest advancements in microRNA research, exploring the therapeutic potential of miRNA-targeting treatments. Register Now! (https://hubs.ly/Q02PPYv80) #microRNA #Therapeutics #Oligonucleotides

CASE STUDY: Uncover the patent protection strategies behind an approved #CAR-T cell therapy. The case study dissects the role of Ark Patent Intelligence in identifying critical patents, exclusivities, and market dynamics. Learn more https://bit.ly/3vMPfdk #cancertreatment #BiotechInnovation #ArkPatentIntelligence

Two pieces of BeiGene news this week: 1️⃣ The end to the collaboration between BeiGene and Shoreline Biosciences. The venture intended to develop NK cell therapies. 2️⃣ Also announced earlier this week, BeiGene shared "that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), has adopted a positive opinion for the approval of tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications." 🔬 Tislelizumab is an hu-IgG4 anti–PD-1 -mab, already approved by the European Commission for advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy, and is also currently under US FDA regulatory review. https://lnkd.in/ey72x3Ev #CellTherapy #Alliances #Innovation #BeiGene #ShorelineBiosciences #Healthcare #Biotech